The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

Bond, M; Rogers, G; Peters, J; Anderson, R; Hoyle, M; Miners, A; Moxham, T; Davis, S; Thokala, P; Wailoo, A; +2 more... Jeffreys, M; Hyde, C; (2012) The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health technology assessment (Winchester, England), 16 (21). pp. 1-470. ISSN 1366-5278 DOI: https://doi.org/10.3310/hta16210

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.3310/hta16210

Abstract

Share

Download

Filename: FullReport-hta16210.pdf

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar